Aldagen Adds $9 Million

Aldagen Inc., a Durham, N.C.-based developer of clinical-stage regenerative therapies, has raised $9 million in additional Series C funding. It brings the round total to $23 million, including a first tranche closed last December. Tullis-Dickerson and CNF Investments were joined by return backers Harbert Venture Partners and Intersouth Partners.